New Delhi, March 25, 2025: The Department of Biotechnology (DBT) has successfully sequenced 10,000 tuberculosis (TB) genome samples as part of its ambitious genomic surveillance initiative. The project, which aims to enhance TB diagnosis and treatment strategies, is on track to achieve its target of sequencing 32,500 samples by November 2025.
This large-scale genome sequencing effort is being carried out under the Indian Tuberculosis Genomic Surveillance Program (ITGSP), a collaborative initiative between DBT, the Indian Council of Medical Research (ICMR), and other research institutions. The goal is to map genetic variations in TB strains across India, enabling the development of more effective diagnostics and targeted therapies.
“By analyzing TB genomes at this scale, we can better understand drug resistance patterns and improve treatment protocols,” said a senior DBT official. “This will play a crucial role in India’s National TB Elimination Program (NTEP) and help achieve the 2025 elimination target.”
The sequencing is being conducted using advanced next-generation sequencing (NGS) technologies at multiple DBT-supported laboratories. Researchers are leveraging the data to identify mutations responsible for antibiotic resistance, which is a major challenge in TB treatment. The insights gained will help in tailoring personalized medicine approaches for TB patients and developing new drug regimens.
India has the world’s highest TB burden, accounting for nearly 27% of global TB cases. Drug-resistant TB is a growing concern, making genome sequencing an essential tool in combating the disease. The DBT’s initiative aligns with the Pradhan Mantri TB Mukt Bharat Abhiyan, a nationwide mission to eliminate TB by 2025.
